Table 1.
Demographics of Japanese (J) and European (E) patients
| Group | Combined J and E | J | E | P (J vs. E) |
|---|---|---|---|---|
| n | 827 | 581 | 246 | |
| Entry criteria | Combined | Consecutive CHF determined by cardiac 123I-mIBG imaging | Candidates for cardiac electronic device treatment | |
| Age (y) | 67.0 ± 12.1 | 68.1 ± 12.3 | 64.4 ± 11.4 | < 0.0001 |
| Male | 639 (77%) | 438 (75%) | 201 (82%) | 0.056 |
| Mean followup (m) | 29.9 ± 14.0 | 29.3 ± 13.4 | 31.5 ± 15.2 | 0.047 |
| NYHA functional classes I, II, III, IV (%) | 62%/23%/13%/2% | 86%/9%/4%/1% | 6%/58%/33%/3% | < 0.0001 |
| Standardized early 123I-mIBG H/M ratio* | 2.00 ± 0.43 | 1.99 ± 0.46 | 2.00 ± 0.37 | 0.95 |
| Standardized late 123I-mIBG H/M ratio* | 1.78 ± 0.42 | 1.77 ± 0.44 | 1.79 ± 0.37 | 0.46 |
| 123I-mIBG washout rate (%) | 10.70 ± 9.6 | 11.0 ± 9.6 | 10.1 ± 9.6 | 0.21 |
| eGFR (mL/min/1.73 m2) | 52.4 ± 29.0 | 44.7 ± 25.5 | 77.5 ± 35.4 | < 0.0001 |
| LVEF (%) | 30.3 ± 10.3 | 31.0 ± 10.8 | 28.8 ± 9.0 | 0.0025 |
| Ischemic etiology | 55% | 52% | 62% | 0.0069 |
| BNP/NT-proBNP grade | 2.4 ± 1.3 | 2.2 ± 1.3 | 3.1 ± 1.1 | < 0.0001 |
| Hemoglobin (g/dL) | 12.0 ± 2.4 | 12.3 ± 2.3 | 11.1 ± 2.4 | < 0.0001 |
| Hypertension (%) | 55% | 48% | 70% | < 0.0001 |
| Diabetes mellitus (%) | 36% | 36% | 36% | 0.95 |
| Hemodialysis (%) | 3% | 4% | 0% | 0.001 |
| ICD/CRTD | 299 (36%) | 121 (21%) | 178 (72%) | < 0.0001 |
*Standardized to MEGP collimator status. BNP, B-type natriuretic peptide; CHF, chronic heart failure; eGFR, estimated glomerular filtration rate; ICD/CRTD, implantable cardioverter defibrillator/cardiac resynchronization therapy with defibrillator; LVEF, left ventricular ejection fraction; MEGP, medium-energy general purpose; mIBG, meta-iodobenzylguanidine; NT-proBNP, N-terminal pro b-type natriuretic peptide; NYHA, New York Heart Association